Why the study?
Availability of hs-cTn measurements at point-of-care can improve timely management of AMI patients, prompting a roadmap for regulatory and analytical validation.
The Atellica VTLi hs-cTnI point-of-care system demonstrated high-sensitivity analytical performance and excellent agreement between plasma and whole blood, supporting its potential use for rapid AMI diagnosis.
No takes yet. Share an insight, caveat, or question.
Supports point-of-care hs-cTnI testing for rapid AMI diagnosis; confirms high-sensitivity performance across matrices.
Christenson et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: